5GV.F GENOVIS AB SE-40
- Market cap
- EUR 143M
- P/E
- 70.5x
- P/B
- 5.17x
- ROE
- 3.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 5GV.F undervalued?
Graham numberThe Graham number of GENOVIS AB SE-40 cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
GENOVIS AB SE-40 fundamental analysis
No fundamental analysis for GENOVIS AB SE-40 yet.
GENOVIS AB SE-40 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About GENOVIS AB SE-40
Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a c…
Full company profileGENOVIS AB SE-40 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
GENOVIS AB SE-40 annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 102M | 158M | 130M | 129M | 136M |
| Gross Profit | 87.4M | 143M | 115M | 116M | 121M |
| Operating Income | 13.8M | 54.9M | 29.4M | 27.8M | 17.2M |
| EBITDA | 15.0M | 66.8M | 60.7M | 42.9M | 32.7M |
| Net Income | 11.2M | 61.5M | 32.9M | 23.5M | 11.1M |
| EPS | 0.17 | 0.94 | 0.50 | 0.36 | 0.17 |
| Balance Sheet | |||||
| Total Assets | 151M | 289M | 327M | 378M | 428M |
| Total Liabilities | 24.9M | 98.0M | 99.4M | 106M | 120M |
| Shareholders' Equity | 126M | 191M | 228M | 272M | 308M |
| Cash & Short-term Investments | 72.8M | 123M | 169M | 163M | 157M |
| Cash Flow | |||||
| Operating Cash Flow | -928K | 67.8M | 37.1M | 32.0M | 48.8M |
| Capital Expenditure | 3.83M | 12.8M | 4.80M | 12.5M | 0.00 |
| Free Cash Flow | -4.75M | 54.9M | 37.1M | 19.5M | 48.8M |
| Ratios | |||||
| ROE | 8.9% | 32.2% | 14.4% | 8.7% | 3.6% |
| ROA | 7.4% | 21.3% | 10.1% | 6.2% | 2.6% |
| Net Profit Margin | 10.9% | 38.9% | 25.3% | 18.2% | 8.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
GENOVIS AB SE-40 dividends
GENOVIS AB SE-40 has not paid dividends in the last 4 fiscal years.
Who owns GENOVIS AB SE-40
- Insiders 16.79%
- Institutions 36.43%
- Public & others 46.78%
- Shares outstanding 67.5M
- Free float 56.5M
GENOVIS AB SE-40 company profile
- Company name
- GENOVIS AB SE-40
- Ticker
- 5GV.F
- ISIN
- SE0002485979
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 36
- Fiscal year end
- December
- Address
- Box 4, Kävlinge, Sweden, 244 21
- Phone
- 46 46 10 12 30
- Website
- genovis.com
About GENOVIS AB SE-40
Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisREX, a protease that digests proteins C-terminally of arginine residues. In addition, the company offers OmniGLYZOR, a mixture of immobilized enzymes; PNGase F, a glycoamidase; OpeRATOR, an O-glycan-specific protease; ImpaRATOR, an O-glycan-dependent protease; OglyZOR, an endoglycosidase; SialEXO, a sialidase product; FucosEXO, a mix of a-Fucosidases; GalactEXO, a ß-Galactosidase mix; GalNAcEXO, an a-N-Acetylgalactosaminidase; and GlycOCATCH, an affinity resin. Further, it provides GlycINATOR (EndoS2), an IgG-specific endoglycosidase; IgGZERO (EndoS), an IgG-specific endoglycosidase; Anti-FabRICATOR (Anti-IdeS), a family of antibody products; and Anti-FabRICATOR Z (Anti-IdeZ), a goat polyclonal antibody, as well as SEQURNA RNase Inhibitor Thermostable. Additionally, the company offers antibodies, proteins, antigens, kits, and cell culture products; bioprocess and gene therapy services; and services, such as SmartEnzymes fragmentation and conjugation, antibody LC-MS analysis, and customized antibody services. It serves biotech and pharmaceutical, contract research, and contract manufacturing companies. The company was founded in 1999 and is headquartered in Kävlinge, Sweden.
GENOVIS AB SE-40 management
5- Mr. Fredrik OlssonPresident & CEO · born 1971
- Mr. Johan DahlbergChief Financial Officer · born 1984
- Ms. Rikke RytterVice President of Sales & Marketing · born 1967
- Ms. Maria EdholmController
- Mr. John M. Lindsay B.A.President of Genovis Inc.